Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Francois-Clement BidardVirginia G KaklamaniPatrick NevenGuillermo StreichAlberto J MonteroFrédéric ForgetMarie-Ange Mouret-ReynierJoo Hyuk SohnDonatienne TaylorKathleen K HarndenHung T KhongJudit KocsisFlorence DalencPatrick M DillonSunil BabuSimon H WatersInes DeleuJosé A García SáenzEmilio BriaMarina Elena CazzanigaJanice LuPhilippe AftimosJavier CortesShubin LiuGiulia ToniniDirk LaurentNassir HabboubiMaureen G ConlanAditya BardiaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
mutations with manageable safety in a phase III trial for patients with ER-positive/HER2-negative advanced breast cancer.
Keyphrases